Globally Colorectal cancer (CRC) is among the most prevalent and deadly cancers. The development of CRC cancer is caused by a step-by-step accumulation of mutations that either turn on oncogenes or turn off suppressor genes. Understanding the biology as well as the genomic landscape of CRC has led to major breakthroughs in developing novel therapeutic targets, improving the clinical management of patients with CRC. However, growing evidence for intratumour heterogeneity limits the use of single-site biopsies in revealing the comprehensive genomic landscape of a tumour. As an expanding array of targeted therapies emerges in clinical practice, the importance of screening tumours for genomic aberrations and understanding resistance mechanisms during disease progression becomes more crucial. Utilizing circulating tumour cells (CTCs) – which can be captured through a minimally invasive blood test – shows potential in offering valuable insights into intratumour heterogeneity and the evolution of tumours. This innovative approach allows for a more holistic understanding of the dynamic characteristics of tumours in real-time as an alternative to invasive procedures. Nonetheless, the actual clinical utility of CTCs in revealing genomic landscape is yet to be fully determined. […]